top of page

Pharmac Update

  • 2 hours ago
  • 3 min read

Kia ora,

 

We are writing to inform you of several upcoming issues.

 

Supply Issues:


  1. Sildenafil (Vedafil) 25mg and 50mg tablets 

  2. Clotrimazole 1% vaginal cream (Clomazol)

  3. Teriparatide Teva Inj 250 mcg per ml

 

Reminder of PSO quantity change and Brand Change:


  1. Furosemide Injection 10 mg per ml, 2 ml ampoule

 

1.Supply Issue: Sildenafil (Vedafil) 25mg and 50mg tablets 


There is a supply issue affecting Vedafil sildenafil 25 mg tablets and Vedafil sildenafil 50 mg tablets due to an issue at the manufacturing site. To support continued access during this supply disruption, Pharmac has secured an alternative brand for the 50mg tablets, Sildenafil (Amarox), this will be listed (funded) from 10 August 2026.

 

Pharmac is working with the supplier to secure an alternative sildenafil 25 mg tablet, which we hope to list (fund) from October 2026. Further details will be communicated on our webpage once the details are confirmed – Sildenafil (Vedafil) 25 and 50 mg tablets: Supply issue

 

Please note the Sildenafil (Amarox) brand is not Medsafe-approved and must be prescribed and supplied in accordance with section 29A of the Medicines Act 1981.

 

Please consider prioritising prescribing the funded sildenafil brands (Vedafil and Sildenafil (Amarox)) for patients receiving funded sildenafil treatment. This will help preserve limited stock and support continuity of access for those who rely on funded treatment during the supply disruption. Supply of the Vedafil brand is expected to return to normal in early 2027.

 

2. Supply Issue: clotrimazole 1% vaginal cream (Clomazol)


There is a supply issue affecting clotrimazole 1% vaginal cream (Clomazol) due to a manufacturing delay.

 

Stock levels are anticipated to become limited from early to mid-August. There may be a temporary out-of-stock period before the next shipment arrives and is released in late August. If the product becomes unavailable, affected patients will need a new prescription to access an alternative treatment option.

 

Pharmac fund a range of treatment options to treat vulvovaginal candidiasis. Clotrimazole 2% vaginal cream (Clomazol) remains available.

 

3. Supply issue: Teriparatide Teva Inj 250 mcg per ml, 2.4 ml


The supplier has notified Pharmac that due to delays there will be a further shortage of Teriparatide Teva Inj 250 mcg per ml, 2.4 ml

  • The alternate Forteo brand was being supplied and now a second alternate S29A product has been sourced.

  • The alternate product is - Teriparatide S29 20 micrograms/80 microlitres, solution for Injection in Pre-filled Pen 2.4 ml

  • Please note that the alternate product expresses the strength differently, but both products contain a total of 600 mcg of teriparatide per 2.4 ml prefilled syringe.

  • The alternate brand was listed (funded) from 10 August 2026, as a mid-cycle listing.

  • The alternate brand is not a Medsafe approved product and should be prescribed and supplied in line with Section 29A of the Medicines Act.

 

4.PSO pack size and brand change: Furosemide Injection 10 mg per ml, 2 ml ampoule


  • Furosemide-AFT Inj 10 mg per ml, 2 ml ampoule was listed (funded) 1 March 2026 and has principal supply status from 1 August 2026 to 30 June 2028.

  • The PSO quantity was increased from 5 to 10 ampoules for furosemide injection 10 mg per ml, 2 ml ampoule from 1 March 2026, to align with the AFT pack size.

 

Please share this information:

Please share this information with your colleagues and within your networks.

 

If you have any questions regarding these supply issues, please contact enquiry@pharmac.govt.nz.

 

Ngā mihi,

Pharmac Implementation Team

__________________________________________________________________

Pharmac | Te Pātaka Whaioranga

PO Box 10-254, Wellington 6140 | Level 9, 40 Mercer Street, Wellington 6011

P: 0800 660 050 | www.pharmac.govt.nz



bottom of page